SCHEMBL4722943

SCHEMBL4722943

CCOC(=O)c1csc(Cc2cc(Cl)ccc2O)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
PTGER1 P34995 2/20 0.49
HSP90AA1 P07900 2/20 0.49
LMNA P02545 2/20 0.48
ANO1 Q5XXA6 1/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
EGFR P00533 1/20 0.47
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 2/20 0.46
KDM4E B2RXH2 1/20 0.45
ALOX15 P16050 2/20 0.43
SLC22A1 O15245 1/20 0.43
USP2 O75604 1/20 0.43
CYP3A4 P08684 1/20 0.43
HSPD1 P10809 1/20 0.43
HSPA5 P11021 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125370 0.86 RAB9A (0.49) MAPTNPC1RAB9AHSP90AA1LMNA
SCHEMBL4767108 0.83 MAPT (0.47) MAPTNPC1RAB9AHSP90AA1LMNA
SCHEMBL4724594 0.83 PTGER1 (0.52) MAPTNPC1RAB9APTGER1HSP90AA1
SCHEMBL5120560 0.82 PTGER1 (0.66) MAPTNPC1RAB9APTGER1HSP90AA1
SCHEMBL4724417 0.82 PTGER1 (0.75) MAPTNPC1RAB9APTGER1HSP90AA1
SCHEMBL5121275 0.81 MAPT (0.58) MAPTNPC1RAB9APTGER1HSP90AA1
SCHEMBL4722380 0.80 PTGER1 (0.75) MAPTNPC1RAB9APTGER1MMP13
SCHEMBL5123454 0.80 MAPT (0.64) MAPTNPC1RAB9APTGER1HSP90AA1
SCHEMBL5216804 0.80 MAPT (0.67) MAPTNPC1RAB9AHSP90AA1LMNA
SCHEMBL3435197 0.79 MAPT (0.54) MAPTNPC1RAB9AHSP90AA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
EP-1874776-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-01-09 EP disclosed
WO-2006114274-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders PTGER1, PTGER2, PTGER4 MAPT 4703/4885NPC1 3020/4885RAB9A 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.